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Background: Pharmacological therapy in patients at high cardiovascular (CV) risk should be tai-
lored to achieve recommended therapeutic targets.
Hypothesis: To evaluate individual global CV risk profile and to estimate the control rates of
multiple therapeutic targets for in adult outpatients followed in real practice in Italy.
Methods: Data extracted from a cross-sectional, national medical database of adult outpatients
in real practice in Italy were analyzed for global CV risk assessment and rates of control of major
CV risk factors, including hypertension, dyslipidemia, diabetes, and obesity. CV risk characteriza-
tion was based on the European SCORE equation and the study population stratified into
3 groups: low risk (<2%), intermediate risk (≥2%–<5%), and high to very high risk (≥5%).
Results: We analyzed data from 7158 adult outpatients (mean age, 57.7 5.3 years; BMI,
28.3 5.0 kg/m2, BP, 136.0 14.3/82.2 8.3 mmHg; total cholesterol, 212.7 40.7 mg/dL), among
whom 2029 (45.2%) had low, 1730 (24.2%) intermediate, and 731 (16.3%) high to very high risk.
Increased SCORE risk was an independent predictor of poor achievement of diastolic BP <90 mm Hg
(OR: 0.852, 95% CI: 0.822–0.882), LDL-C < 130 mg/dL (OR: 0.892, 95% CI: 0.861–0.924), HDL-
C > 40 (males)/>50 (females) mg/dL (OR: 0.926, 95% CI: 0.895–0.958), triglycerides <160 mg/dL
(OR: 0.925, 95% CI: 0.895–0.957), and BMI <25 kg/m2 (OR: 0.888, 95% CI: 0.851–0.926), even after
correction for diabetes, renal function, pharmacological therapy, and referring physicians (P < 0.001).
Conclusions: Despite low prevalence and optimal medical therapy, individuals with high to very
high SCORE risk did not achieve recommended therapeutic targets in a real-world practice.
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1 | INTRODUCTION
Cardiovascular (CV) diseases continue to represent by far the leading
cause of morbidity and mortality in various countries, including
Italy.1,2 Several surveys reported persistently low rates of control of
major CV risk factors, including hypertension (HTN), hypercholesterol-
emia, atherogenic dyslipidemia, and diabetes mellitus (DM), in both
North American 3 and European4–7 countries.
A major driver for the insufficient control rates of major CV risk
factors often has been related to the relatively low standard of care
provided by treating physicians. This seems to be linked, among
others, to various factors, including time restrictions during clinical
consultations, inadequate knowledge and application of guidelines'
recommendations, and lack of application of timely and integrated
pharmacological and nonpharmacological interventions.8,9 For these
reasons, implementation of preventive measures has been proposed
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as a cornerstone of healthcare policies.10 In this view, the central role
of individual global CV risk stratification has been recently reaffirmed
to early identify and promptly treat asymptomatic high-risk individuals
and reduce the incidence of CV outcomes, mostly in the setting of pri-
mary care.11
The Evaluation of Final Feasible Effect of Control Training and
Ultra-sensitisation (EFFECTUS) survey showed a very high prevalence
of CV risk factors among adult outpatients followed by different
groups of Italian physicians, mostly general practitioners (GPs).12 Fur-
ther analyses from the same database were performed to detect
potentially different approaches according to local disparities,13 avail-
ability of electronic support,14 and predefined subsets of outpatients,
such as those with DM or HTN.15,16 However, specific analysis testing
the achievement of different multiple therapeutic targets according to
risk score estimation was not available.
On the basis of these considerations, and in view of the large and
representative population sample of this database, we aimed here to
evaluate individual global CV risk profile by using the European Sys-
tematic Coronary Risk Evaluation (SCORE) risk model and to estimate
the control rates of multiple therapeutic targets for HTN, dyslipidemia,
obesity, and DM in this large cohort of adult outpatients followed in
real practice in Italy.
2 | METHODS
2.1 | Study methodology
The methodology of the study has been previously described.12
Briefly, the EFFECTUS survey was designed to evaluate prevalence
and control rates of major CV risk factors, as well diagnostic opportu-
nities and treatment habits of physicians in a setting of real practice in
Italy. The program was addressed to physicians operating in both gen-
eral practice and outpatient clinics across the entire national territory
and was aimed at improving quality standards for cardiovascular dis-
ease (CVD) management and control in Italy.
Written invitations were forwarded in a sizable number to ensure
a sufficiently representative sample of the study population and to
achieve this target within a period of approximately 3 to 4 weeks. For
this purpose, each of the 20 to 24 regional referral centers invited
60 physicians per region (35 GPs, 15 cardiologists, and 10 diabetolog-
ists) to participate to this survey, for a total of 1400 individual physi-
cians, selected on the basis of the above-mentioned clinical habits and
personal characteristics. Then, approximately 1250 invitations were
issued and physicians were asked to fill out questionnaires featuring
their characteristics and practice (age, sex, geographic location, pro-
fessional expertise, use of electronic database) and to reply anony-
mously to the administrative sites of their regional referral centers.
Following their acceptance, involved physicians were asked to
report clinical data extracted from their clinical records from 10 con-
secutive adult Caucasian outpatients age > 40 years, whatever the
reason they referred to their own attending physicians. The entire
data collection was completed by participants on-site and then deliv-
ered to the data-collection center by online access to a remote data-
base. At each study site, collection of data was conducted during
1 week in May 2006. Physicians who completed the program did not
receive any compensation for their participation.
2.2 | Data collection
Data collection included full medical history and physical examination.
Information was obtained on current therapy for HTN, dyslipidemia,
DM, and concomitant CV diseases and comorbidities, including coro-
nary artery disease, stroke, and heart failure, as well as any concomi-
tant medication. Calculation was made of body mass index (BMI),
expressed as body weight in kilograms divided by the square of height
in meters (kg/m2). Clinic systolic and diastolic blood pressure
(BP) levels, serum levels of total cholesterol (TC), high-density lipopro-
tein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C),
triglycerides (TG), glucose, glycated hemoglobin (HbA1c), and creati-
nine were extracted from available clinical records. Available data
were centrally analyzed for global CV risk evaluation and CV risk pro-
file characterization.
The study conformed to the Declaration of Helsinki and its subse-
quent modifications and was authorized by the reference ethics com-
mittee. The confidentiality of the data was carefully and strictly
protected.
2.3 | Definition of risk factors, markers of organ
damage, and comorbidities
HTN was defined as systolic BP ≥140 mm Hg and/or diastolic BP
≥90 mm Hg in untreated subjects or in the presence of stable
(≥6 months) antihypertensive drug treatment.17 Diagnosis of hyper-
cholesterolemia was made based on TC levels ≥190 mg/dL, LDL-C
levels ≥130 mg/dL, or stable lipid-lowering drug treatment in both
conditions.18–20 Obesity was defined as BMI ≥25 kg/m2.21 Finally,
DM was defined as fasting plasma glucose levels ≥126 mg/dL.22–24
Coronary artery disease was defined according to the presence of
acute coronary syndrome.25–27 Finally, nonfatal stroke was defined as
a neurological deficit with sudden onset and persistence of symptoms
for >24 hours or leading to death with no apparent causes other than
vascular ones.28 Transient ischemic attack was defined as a neurologi-
cal event with the signs and symptoms of stroke that resolves within
a short period of time (typically lasting 2 to 30 minutes).29
Chronic kidney disease (CKD) was defined as eGFR <60 mL/
min/1.73 m2, whereas severe CKD was defined as eGFR <30 mL/
min/1.73 m2 or dialysis.
2.4 | Risk score models
CV risk was estimated by using European SCORE risk equation, which
provides the 10-year risk of fatal events for patients age 40 to
65 years.30 Risk estimation for developing fatal coronary events is
based on the following items for the equation: TC, systolic BP, age,
and smoking status.30 The study population was composed of adult
Caucasian individuals born and living in Italy; therefore, the low-risk
score charts have been applied.30 Included patients were stratified
into 3 groups: low SCORE risk (<2%), intermediate SCORE risk (≥2%–
<5%), and high to very high SCORE risk (≥5%).30
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2.5 | Therapeutic targets
The following therapeutic targets were set for predefined CV risk fac-
tors: systolic/diastolic BP <140/90 mm Hg in patients with essential
HTN and < 140/85 mm Hg in DM patients with HTN,17 BMI ≤25 kg/
m2,21 HDL-C ≥ 40 mg/dL in males and ≥ 50 mg/dL in females,19,20
TG ≤150 mg/dL,19,20 and fasting glucose ≤126 mg/dL.22
2.6 | Statistical analysis
Data were entered into Microsoft Access for Windows (Microsoft
Corp., Redmond, WA). Baseline characteristics of patients are pre-
sented as number and percentage for dichotomous variables and
mean SD for continuous variables. Normal distribution of data was
assessed using histograms and the Kolmogorov–Smirnov test. Differ-
ences between continuous variables were assessed using ANOVA
test. Categorical variables were compared among groups by the χ2
test. To evaluate the relationship between European SCORE risk and
control rates of different therapeutic targets (ie, those not already
included in the SCORE risk equation), odds ratios (OR) and 95% confi-
dence intervals (CI) were derived from logistic regression analysis. A
multivariable model was fitted with baseline covariates that showed
differences at the <0.05 significance level. All tests were 2-sided, and
a P value <0.05 was considered statistically significant. All calculations
were generated using SPSS software, version 20.0 (IBM Corp.,
Armonk, NY).
3 | RESULTS
3.1 | Study population
From an overall sample of 16 645 adult outpatients included in the
original database, we selected 7158 (43.0%) records with valid clinical
data and patient age between 40 and 65 years, among whom the vast
majority (77.6%) were followed by GPs. In this sample, 2029 (45.2%)
patients had low SCORE risk, 1730 (24.2%) had intermediate SCORE
risk, and 731 (16.3%) had high to very high SCORE risk.
3.2 | Distribution of CV risk factors and
comorbidities
General characteristics of the study population stratified in different
SCORE risk groups are reported in Table 1. There were significantly
more male individuals in the intermediate-risk and high-risk categories
compared with the low-risk group (P < 0.001). As expected, all CV risk
factors, such as sedentary lifestyle, smoking, dyslipidemia, and HTN,
as well as associated clinical conditions such as coronary and cerebro-
vascular diseases, showed a significant trend toward increase from
low to high risk categories (P < 0.001 for all comparisons, with the
only exception of family history of CVD, P = 0.03). CKD was signifi-
cantly more prevalent in low-risk individuals compared with other
groups (P < 0.001).
Similarly, systolic and diastolic BP levels, TC and LDL-C, TG,
glucose, and serum creatinine levels showed a significant trend
toward increase from the low-risk category to the high- to very
high-risk category, whereas HDL-C levels and eGFR showed a sig-
nificant reduction from the former to the latter groups of individ-
uals. Indeed, significant correlations with European SCORE risk were
observed for all tested variables, including diastolic BP (r = 0.286;
P < 0.001), LDL-C (r = 0.221; P < 0.001), HDL-C (r = −0.121;
P < 0.001), TG (r = 0.145; P < 0.001), and BMI (r = 0.072;
P < 0.001).
3.3 | Pharmacological and nonpharmacological
interventions
As illustrated in Table 1, recommendations for smoking cessation, diet,
and physical activity were more frequently prescribed in patients in
the high-risk categories compared with those at intermediate and low
risk (P < 0.001 for all comparisons).
Patients at high to very high risk also received more drug thera-
pies for HTN (P < 0.001) and dyslipidemia (P < 0.001), as well as more
antiplatelet agents (P < 0.001), compared with other groups, whereas
no significant differences were found among groups with regard to
antidiabetic therapy.
3.4 | Achievement of predefined therapeutic targets
Proportions of patients achieving the recommended therapeutic tar-
gets for major CV risk factors are reported in Table 2. Control rates of
both systolic BP and TC levels were significantly lower in patients at
high to very high SCORE risk compared with those at low or interme-
diate risk (P < 0.001 for both comparisons). Also, proportions of
patients achieving the recommended therapeutic targets for addi-
tional CV risk, including diastolic BP, LDL-C and HDL-C, TG, BMI, and
glucose levels, were significantly lower in the high-risk group than in
other groups of outpatients (P < 0.001 for all comparisons). The same
trends were also observed in patients under pharmacological thera-
pies (Figure 1). In treated hypertensive patients (n = 4485), among
whom 20.4% were in the high-risk group, 1703 (42.0%) achieved the
systolic BP goal of <140 mm Hg, 2655 (65.5%) achieved the diastolic
BP goal of <90 mm Hg, and 1512 (37.3%) achieved the recommended
therapeutic target for BP <140/90 mm Hg. In treated dyslipidemic
patients (n = 2442), among whom 21.3% were in the high-risk group,
699 (42.4%) achieved the LDL-C goal of <130 mg/dL. Finally, in trea-
ted patients with DM (n = 1887), among whom 17.7% were in the
high-risk group, 355 (23.9%) achieved the glucose goal of <126 mg/
dL and 86 (6.8%) achieved the HbA1c goal of <6% (available in
n = 1960 DM patients).
3.5 | Univariate and multivariate analysis
These analyses are reported in Table 3 for the overall population sam-
ple, for patients with DM, and for patients at very high CV risk with
previous myocardial infarction or stroke. In the total population,
increased SCORE risk resulted an independent predictor of poor
achievement of diastolic BP <90 mm Hg (OR: 0.852, 95% CI:
0.822–0.882), LDL-C < 130 mg/dL (OR: 0.892, 95% CI:
0.861–0.924), HDL-C > 40 mg/dL (in males) and > 50 mg/dL
(in females; OR: 0.926, 95% CI: 0.895–0.958), TG <160 mg/dL (OR:
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0.925, 95% CI: 0.895–0.957), and BMI <25 kg/m2 (OR: 0.888, 95%
CI: 0.851–0.926), even after correction for DM, renal function, phar-
macological therapy, and referring physicians (P < 0.001). The same
results were observed in patients with DM, although European
SCORE risk did not predict the achievement of glucose control in this
high-risk category. Similarly, SCORE showed no significant predictive
TABLE 1 General characteristics of adult outpatients, stratified according to European SCORE
Parameters Low Risk, n = 2029 (45.2) Intermediate Risk, n = 1730 (24.2) High to Very High Risk, n = 731 (16.3) P Value
Female sex 1436 (71.0) 488 (28.2)a 61 (8.3)a,b <0.001
Age, y 55.1  5.3 59.8 4.0 61.6 3.1 <0.001
BMI, kg/m2 28.1 5.3 28.5 4.8 28.9 4.4 0.003
WC, cm 97.5 17.0 100.4 14.3 103.8 14.4 <0.001
Clinical parameters
SBP, mm Hg 130.7 12.5 137.5 12.7 146.7 14.4 <0.001
DBP, mm Hg 80.3 7.9 82.6 7.5 86.1 8.5 <0.001
TC, mg/dL 205.0 38.0 212.9 39.2 230.6 42.8 <0.001
HDL-C, mg/dL 52.2 13.4 50.4 12.7 48.0 11.5 <0.001
LDL-C, mg/dL 127.0 38.1 133.2 37.6 148.3 41.3 <0.001
TG, mg/dL 150.9 75.0 165.2 88.3 178.7 78.5 <0.001
Glucose, mg/dL 118.5 42.7 122.2 42.8 126.3 44.2 <0.001
sCr, mg/dL 0.9 0.2 1.0 0.3 1.1 0.3 <0.001
eGFR, mg/mL/1.72 m2 89.1 32.6 94.9 64.4 90.4 32.7 0.015
CV risk factors
Fx CVD 622 (30.7) 546 (31.6) 273 (37.3)a,b 0.03
Sedentary lifestyle 1399 (69.0) 1144 (66.1) 489 (66.9) 0.169
Smoking 455 (22.4) 712 (41.2)a 617 (84.4)a,b <0.001
Dyslipidemia 935 (46.1) 946 (54.7)a 471 (64.4)a,b <0.001
HTN 1172 (57.8) 1201 (69.4)a 608 (83.2)a,b <0.001
Obesity 1103 (70.2) 1034 (77.2)a 478 (83.1)a,b <0.001
DM 664 (32.7) 635 (36.7)a 289 (39.5)a 0.001
Comorbidities
CAD 241 (11.9) 358 (20.7)a 166 (22.7)a <0.001
MI 160 (7.9) 234 (13.5)a 99 (13.5)a <0.001
Angina 79 (3.9) 111 (6.4)a 70 (9.6)a,b <0.001
CABG 121 (6.0) 202 (11.7)a 70 (9.6)a <0.001
Cerebrovascular disease 48 (2.4) 50 (2.9) 38 (5.2)a,b 0.001
Stroke 25 (1.2) 20 (1.2) 14 (1.9) 0.290
TIA 32 (1.6) 28 (1.6) 34 (4.7)a,b <0.001
PAD 112 (5.5) 165 (9.5)a 100 (13.7)a,b <0.001
CKD 139 (11.9) 82 (8.1)a 29 (6.7)a 0.001
Severe CKD 7 (0.3) 2 (0.1) 2 (0.3) 0.194
Nonpharmacological advice
Smoking cessation 766 (37.8) 859 (49.7)a 510 (69.8)a,b <0.001
Weight reduction 1474 (72.6) 1348 (77.9)a 578 (79.1)a <0.001
Physical activity 1403 (69.1) 1300 (75.1)a 555 (75.9)a <0.001
Drug therapy
BP-lowering Tx 1314 (64.8) 1351 (78.1)a 638 (87.3)a,b <0.001
Lipid-lowering Tx 856 (42.2) 880 (50.9)a 440 (60.2)a,b <0.001
Glucose-lowering Tx 638 (31.4) 597 (34.5)a 255 (34.9)a,b 0.078
Antiplatelet Tx 599 (29.5) 722 (41.7)a 403 (55.1)a,b <0.001
Abbreviations: BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CKD, chronic kidney dis-
ease; CV, cardiovascular; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; Fx CVD, family history of cardio-
vascular disease; HDL-C, high-density lipoprotein cholesterol; HTN, hypertension; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction;
PAD, peripheral arterial disease; SBP, systolic blood pressure; SCORE, Systematic Coronary Risk Evaluation; sCr, serum creatinine; SD, standard deviation;
TC, total cholesterol; TG, triglycerides; TIA, transient ischemic attack; Tx, treatment; WC, waist circumference. Data are presented as n (%) or mean SD.
a P < 0.05 vs low risk.
b P < 0.05 vs intermediate risk.
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value of glucose and BMI control in those patients with previous myo-
cardial infarction or stroke.
4 | DISCUSSION
In the present analysis, we applied the European SCORE risk equation
to evaluate individual global CV risk profile and estimated rates of
control of both conventional and additional CV risk factors in adult
outpatients predominantly followed by GPs in a setting of real prac-
tice in Italy.
In view of the characteristics of the applied risk score calculator,
which cannot be used in people age < 40 years or > 65 years, for the
purpose of the present analysis we considered only data from those
individuals aged 40 to 65 years. In this sample, we observed high
prevalence of all major CV factors, particularly in high-risk and very
high-risk categories of adult outpatients, thus confirming the high bur-
den of CVD in the adult population in our country. This high preva-
lence of risk factors, mostly HTN and hypercholesterolemia, was
paralleled by high risk score estimations and relatively low control
rates, independently by the presence or absence of pharmacological
therapies and other comorbidities. These observations were consis-
tent with previous clinical studies performed on the same database,12
as well as with other clinical studies performed in the setting of clinical
practice in Italy, which reported that the proportions of high-risk
patients who achieved the recommended BP targets were relatively
low (about 30%).31,32 As an example, in the European Study on Car-
diovascular Risk Prevention and Management in Usual Daily Practice
(EURIKA), about 40% of the study population had high SCORE risk;
and control rates of major CV risk factors, including HTN, dyslipide-
mia, DM, and BMI, were similar to those reported in our analysis.33
The same results were also reported in the European Action on Sec-
ondary and Primary Prevention by Intervention to Reduce Events III
(EUROASPIRE III),5 as well as in the National Health and Nutrition
Examination Surveys (NHANES).34
The failure in achieving the recommended therapeutic targets
cannot be explained by poor quality of the clinical data or low aware-
ness of global CV risk estimation, as we observed significant correla-
tions among all tested clinical parameters and SCORE risk estimations.
In other words, included physicians had all the requested clinical infor-
mation for CV risk estimation, and, thus, cannot be unaware of the
level of risk of their patients; yet they were not able to achieve the
TABLE 2 Control of major CV risk factors in adult outpatients, stratified according to European SCORE
Parameters Low Risk Intermediate Risk High to Very High Risk P Value
Major CV risk factors
SBP <140 mm Hg 1394 (68.7) 831 (48.0) 172 (23.5) <0.001
TC <190 mg/dL 657 (32.4) 425 (24.6) 106 (14.5) <0.001
Additional CV risk factors
DBP <90 mm Hg 1640 (80.8) 1280 (74) 411 (56.2) <0.001
LDL-C < 130 mg/dL 960 (56.2) 718 (48.9) 217 (34.7) <0.001
HDL-C ≥ 40 (M)/ ≥50 (F) mg/dL 937 (53.2) 740 (49.2) 243 (38.2) <0.001
TG <160 mg/dL 1010 (53.8) 748 (46.9) 238 (35.5) <0.001
Glucose <126 mg/dL 1336 (71.3) 1072 (67.8) 435 (64.4) 0.002
BMI <25 kg/m2 468 (29.8) 305 (22.8) 97 (16.9) <0.001
Abbreviations: BMI, body mass index; CV, cardiovascular; DBP, diastolic blood pressure; F, females; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; M, males; SBP, systolic blood pressure; SCORE, Systematic Coronary Risk Evaluation; SD, standard deviation; TC, total
cholesterol; TG, triglycerides. Data are presented as n (%) or mean SD. Major risk factors (eg, SBP and TC levels) are included in the European SCORE risk
equation, whereas other additional risk factors, such as DBP, LDL-C, HDL-C, TG, and BMI, were not included.
FIGURE 1 Proportions of patients
achieving the recommended therapeutic
targets for SBP/DBP, total cholesterol, and
fasting glucose levels according to
European SCORE. Proportions of patients
on targets have been calculated among
treated patients with HTN, treated patients
with DYS, and treated outpatients with
DM, respectively. Abbreviations: DBP,
diastolic blood pressure; DM, diabetes
mellitus; DYS, dyslipidemia; GLUC, glucose;
HTN, hypertension; LDL, low-density
lipoprotein cholesterol; SBP, systolic blood
pressure; SCORE, Systematic Coronary
Risk Evaluation; TOT-C, total cholesterol
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TABLE 3 Univariate and multivariate analyses for European SCORE risk and the achievement of different therapeutic targets in the overall
population sample, in patients with DM, and in patients with previous MI or stroke
Parameters OR (95% CI) P Value
Overall population, N = 7158
European SCORE*DBP <90 mm Hg
Unadjusted 0.833 (0.812–0.854) <0.001
Adjusted (physicians, DM, BMI, eGFR,
antihypertensive Tx)
0.852 (0.822–0.882) <0.001
European SCORE*LDL-C < 130 mg/dL
Unadjusted 0.863 (0.840–0.887) <0.001
Adjusted (physicians, DM, BMI, eGFR,
lipid-lowering Tx)
0.892 (0.861–0.924) <0.001
European SCORE*HDL-C > 40 mg/dL
(M) and > 50 mg/dL (F)
Unadjusted 0.913 (0.890–0.937) <0.001
Adjusted (physicians, DM, BMI, eGFR,
lipid-lowering Tx)
0.926 (0.895–0.958) <0.001
European SCORE*TG <160 mg/dL
Unadjusted 0.897 (0.874–0.920) <0.001
Adjusted (physicians, DM, BMI, eGFR,
lipid-lowering Tx)
0.925 (0.895–0.957) <0.001
European SCORE*Glucose <126 mg/dL
Unadjusted 0.955 (0.933–0.978) <0.001
Adjusted (physicians, BMI, eGFR,
glucose-lowering Tx)
0.962 (0.918–1.008) 0.100
European SCORE*BMI <25 kg/m2
Unadjusted 0.885 (0.854–0.917) <0.001
Adjusted (physicians, DM, eGFR) 0.888 (0.851–0.926) <0.001
Patients with DM
European SCORE*DBP <90 mm Hg
Unadjusted 0.854 (0.820–0.890) <0.001
Adjusted (physicians, BMI, eGFR,
antihypertensive Tx)
0.860 (0.814–0.908) <0.001
European SCORE*LDL-C < 130 mg/dL
Unadjusted 0.868 (0.831–0.907) <0.001
Adjusted (physicians, BMI, eGFR,
lipid-lowering Tx)
0.892 (0.845–0.941) <0.001
European SCORE*HDL-C > 40 mg/dL
(M) and > 50 mg/dL (F)
Unadjusted 0.936 (0.989–0.975) 0.001
Adjusted (physicians, BMI, eGFR,
lipid-lowering Tx)
0.912 (0.862–0.965) 0.001
European SCORE*TG <160 mg/dL
Unadjusted 0.942 (0.905–0.980) 0.003
Adjusted (physicians, BMI, eGFR,
lipid-lowering Tx)
0.951 (0.903–1.002) 0.061
European SCORE*BMI <25 kg/m2
Unadjusted 0.893 (0.837–0.952) 0.001
Adjusted (physicians, eGFR) 0.896 (0.833–0.964) 0.003
European SCORE*Glucose <126 mg/dL
Unadjusted 0.974 (0.933–1.017) 0.236
Patients with previous stroke or MI
European SCORE*DBP <90 mm Hg
Unadjusted 0.784 (0.728–0.845) <0.001
Adjusted (physicians, DM, BMI, eGFR,
antihypertensive Tx)
0.746 (0.670–0.831) <0.001
European SCORE*LDL-C < 130 mg/dL
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recommended therapeutic targets in their daily clinical practice. Also,
poor control rates of CV risk factors cannot be related to the insuffi-
cient pharmacological and nonpharmacological therapies, because the
higher the risk profile, the higher the proportions of patients who
received educational advice and drug therapies (also in combined for-
mulations). Many of the previous studies have supported a lesser con-
trol of risk factors in high-risk patients but associated with a similar
proportion of treated patients supporting some degree of therapeutic
inertia. This does not seem the case in the present study. Maybe the
doses of drugs, the use of combinations, and the medication preferen-
tially used represent some factors that may at least in part explain the
apparent discrepancy between the higher rate of treatment and the
lesser control of risk factors.
High SCORE risk estimations were an independent predictor of
lower rates of control of all tested CV risk factors, not only systolic BP
and TC (which are included in the risk equation), but also for additional
risk factors, such as diastolic BP, LDL-C and HDL-C levels, TG, fasting
glucose, and BMI (not included in the equation). These results were
largely independent by the presence of pharmacological therapies and
other covariates, including renal function and type of referring physi-
cian, and strongly support the use of the SCORE algorithm in a setting
of real-world practice to help physicians for better identify high-risk
individuals and implement preventive strategies for reducing the bur-
den of CVD.
4.1 | Study limitations
The present study has some potential limitations that should be
acknowledged.15,16 First of all, it is based on a large, cross-sectional,
descriptive survey. Second, dependence on physician self-reporting
throughout predefined standardized questionnaires, rather than direct
measures or quantifications of the tested variables, may create poten-
tial biases. Finally, patients included in the present analysis were con-
secutively enrolled about 10 years ago. During this time period,
several sets of guidelines and recommendations from national and
international societies have been produced, often proposing contrast-
ing diagnostic thresholds and therapeutic targets for major CV risk
factors and comorbidities. It should be noted, however, that BP tar-
gets were substantially unchanged over time, and that different LDL-
C targets have been considered in the present analysis, thus being in
line with current recommendations from international guidelines.
5 | CONCLUSION
In our analysis, we observed higher prevalence of uncontrolled major
CV risk factors in adult outpatients with high SCORE risk profile. In
these individuals, despite greater use of pharmacological drugs and
recommendations for adopting favorable lifestyle measures, lower
rates of control were observed, independently by referring physicians
and other clinical characteristics. Further investigations should be per-
formed to better identify potential causes of the observed relatively
poor control rates of major risk factors to implement prevention of
major CV outcomes in Italy.
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